Roth Capital Issues Negative Forecast for CervoMed Earnings

CervoMed Inc. (NASDAQ:CRVO) – Equities researchers at Roth Capital cut their Q1 2025 earnings per share estimates for CervoMed in a research note issued to investors on Tuesday, March 18th. Roth Capital analyst B. Pachaiyappan now anticipates that the company will post earnings per share of ($0.80) for the quarter, down from their previous estimate of ($0.52). Roth Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share. Roth Capital also issued estimates for CervoMed’s Q2 2025 earnings at ($0.73) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.44) EPS and FY2025 earnings at ($2.47) EPS.

CRVO has been the subject of a number of other reports. Brookline Capital Management raised CervoMed from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 11th. HC Wainwright cut CervoMed from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 17th. Jones Trading upgraded CervoMed from a “hold” rating to a “buy” rating and set a $15.00 price target for the company in a research report on Thursday, March 13th. D. Boral Capital restated a “buy” rating and issued a $10.00 target price on shares of CervoMed in a report on Monday. Finally, Morgan Stanley restated an “underweight” rating on shares of CervoMed in a report on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, CervoMed has a consensus rating of “Moderate Buy” and an average target price of $27.50.

CervoMed Stock Up 23.4 %

CervoMed stock opened at $11.56 on Thursday. CervoMed has a 52 week low of $1.80 and a 52 week high of $25.92. The company has a market capitalization of $71.33 million, a price-to-earnings ratio of -5.69 and a beta of 1.84. The stock has a 50-day moving average price of $3.06 and a 200 day moving average price of $7.90.

CervoMed (NASDAQ:CRVO) last posted its earnings results on Monday, March 17th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.13). The company had revenue of $2.16 million during the quarter, compared to analysts’ expectations of $1.51 million. CervoMed had a negative net margin of 118.68% and a negative return on equity of 44.11%.

Hedge Funds Weigh In On CervoMed

Several hedge funds and other institutional investors have recently made changes to their positions in CRVO. Woodline Partners LP acquired a new stake in shares of CervoMed during the 4th quarter worth about $175,000. Nuveen Asset Management LLC boosted its stake in shares of CervoMed by 113.6% in the fourth quarter. Nuveen Asset Management LLC now owns 41,569 shares of the company’s stock valued at $97,000 after buying an additional 22,104 shares in the last quarter. BNP Paribas Financial Markets purchased a new stake in shares of CervoMed in the fourth quarter valued at approximately $32,000. Mariner LLC purchased a new stake in CervoMed during the fourth quarter worth $30,000. Finally, DRW Securities LLC purchased a new stake in CervoMed during the fourth quarter worth $30,000. Hedge funds and other institutional investors own 25.15% of the company’s stock.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.